Related Experiment Videos
[Plasma fibronectin determination in acute bacterial pneumonia]
Hua Xi Yi Ke Da Xue Xue Bao = Journal of West China University of Medical Sciences = Huaxi Yike Daxue Xuebao
|March 1, 1992
Summary
Plasma fibronectin (PFn) levels are significantly lower in patients with acute bacterial pneumonia. Lower PFn indicates disease severity and aids in monitoring recovery and prognosis.
Area of Science:
- Biochemistry
- Immunology
- Clinical Medicine
Context:
- Acute bacterial pneumonia is a significant cause of morbidity and mortality.
- Plasma fibronectin (PFn) is a glycoprotein involved in immune response and tissue repair.
- Understanding biomarkers for pneumonia is crucial for effective patient management.
Purpose:
- To investigate the correlation between plasma fibronectin levels and acute bacterial pneumonia.
- To assess the utility of PFn as a biomarker for disease severity and clinical course.
Summary:
- Plasma fibronectin levels were measured in healthy adults and patients with acute bacterial pneumonia using immunoelectrophoresis.
- PFn levels were significantly lower in pneumonia patients compared to healthy controls (214.49 ± 77.84 vs. 292.48 ± 43.11 µg/ml, P < 0.001).
- Severe pneumonia cases exhibited markedly reduced PFn levels (127.45 ± 31.03 µg/ml) compared to mild/moderate cases (255.11 ± 54.16 µg/ml, P < 0.001).
- During recovery, PFn levels increased significantly (213.13 ± 41.32 µg/ml) compared to the exacerbation period (154.52 ± 51.27 µg/ml, P < 0.001).
Impact:
- Plasma fibronectin levels serve as a valuable indicator for assessing the clinical course of acute bacterial pneumonia.
- PFn measurements can aid in predicting prognosis and guiding therapeutic interventions for pneumonia patients.
- This study highlights PFn as a potential biomarker for monitoring pneumonia progression and recovery.